Publications by authors named "Aaron Bao"
Prurigo nodularis (PN) is a chronic inflammatory skin condition frequently associated with atopy, yet the relationship between atopic status and comorbidity profiles in PN patients remains poorly understood. Using the 2016-2019 National Inpatient Sample database, we analyzed 7,765 patients with PN to compare epidemiological characteristics and comorbidity patterns between atopic and non-atopic cohorts. Among these patients, 1,545 (19.
View Article and Find Full Text PDFArticle Synopsis
- - Central centrifugal cicatricial alopecia (CCCA) primarily affects Black women and is characterized by scarring that leads to hair loss; conventional treatments focus on inflammation rather than the underlying fibrotic issues.
- - A study was conducted to assess the effects of low-dose oral metformin, an antidiabetic drug with antifibrotic properties, on clinical symptoms and gene expression in CCCA patients unresponsive to standard treatments.
- - Results from 12 participants showed that after at least 6 months of metformin treatment, many experienced symptom improvement and some showed hair regrowth, with gene analysis indicating beneficial changes in pathways related to skin and hair development.
Background: Steroid-resistant nephrotic syndrome (SRNS) is the second most frequent cause of chronic kidney disease in children and young adults. The most severe form of steroid-resistant nephrotic syndrome is congenital nephrotic syndrome Finnish type (CNSF), caused by biallelic loss-of-function variants in NPHS1, encoding nephrin. Since each of the 68 monogenic causes of steroid-resistant nephrotic syndrome represents a rare cause of the disease, tailoring therapeutic interventions to multiple molecular targets remains challenging, suggesting gene replacement therapy (GRT) as a viable alternative.
View Article and Find Full Text PDFThe association of atopic dermatitis and cutaneous T-cell lymphoma: A multicentre cohort study.
J Eur Acad Dermatol Venereol
February 2025
Article Synopsis
- Prurigo nodularis (PN) is a chronic skin condition marked by severe itching and skin nodules, and it may also involve systemic inflammation linked to other health issues.
- A study investigated the effects of dupilumab, a newly approved treatment for PN, on inflammatory proteins in blood samples from three patients after six months of therapy.
- Results showed significant clinical improvements and a reduction in various inflammatory proteins related to different immune pathways, suggesting dupilumab could help alleviate both skin symptoms and systemic inflammation risks.
Background: Steroid-resistant nephrotic syndrome is the second leading cause of chronic kidney disease among patients < 25 years of age. Through exome sequencing, identification of > 65 monogenic causes has revealed insights into disease mechanisms of nephrotic syndrome (NS).
Methods: To elucidate novel monogenic causes of NS, we combined homozygosity mapping with exome sequencing in a worldwide cohort of 1649 pediatric patients with NS.
Background: Chronic pruritus (CP) is a poorly characterized condition associated with intense pruritus without a primary skin eruption. This condition tends to emerge more commonly in older adults, and there is limited research on triggering factors.
Objective: To explore the clinical characteristics and pathophysiology of CP following exposure to an immune stimulus.
Background: Steroid-resistant nephrotic syndrome is the second leading cause of chronic kidney disease among patients <25 years of age. Through whole exome sequencing, identification of >65 monogenic causes has rendered insights into disease mechanisms of nephrotic syndrome.
Methods: To elucidate novel monogenic causes of NS, we combined homozygosity mapping with ES in a worldwide cohort of 1649 pediatric patients with NS.
Prurigo nodularis (PN) is a chronic inflammatory skin disease that is associated with variability in peripheral blood eosinophil levels and response to T-helper 2 targeted therapies (Th2). Our objective was to determine whether circulating immune profiles with respect to type 2 inflammation differ by race and peripheral blood eosinophil count. Plasma from 56 PN patients and 13 matched healthy controls was assayed for 54 inflammatory biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of anifrolumab, a monoclonal antibody, on patients with refractory cutaneous lupus erythematosus (CLE) and other skin issues related to systemic lupus erythematosus (SLE).
- Four SLE patients received anifrolumab as an additional treatment, and their symptoms were tracked using the CLASI-A index before and after treatment.
- Results showed significant improvements in skin conditions, including a sharp decrease in CLASI-A scores and better management of symptoms, indicating that anifrolumab is a promising treatment option for resistant cases of CLE in SLE patients, though more research is required.